Telmisartan — 40mg × 30 Caps | ARB PPAR-γ Research

Telmisartan is a selective angiotensin II receptor type 1 (AT1) antagonist small molecule originally developed by Boehringer Ingelheim, characterized in academic and clinical research literature as pharmacologically unique among the angiotensin receptor blocker (ARB) class due to its additional partial PPAR-γ (peroxisome proliferator-activated receptor gamma) agonist activity. This dual mechanism — AT1 receptor antagonism plus PPAR-γ partial agonism — distinguishes telmisartan from other ARBs (losartan, valsartan, olmesartan, candesartan, irbesartan) and has generated substantial research literature interest in cardiovascular research, metabolic research, and PPAR-γ pharmacology research. Telmisartan also has the longest plasma half-life in the ARB class (~24 hours), positioning it as a research reference compound for extended-duration AT1 receptor antagonism research. This 40mg oral capsule format corresponds to a standard maintenance dose format established in the extensive telmisartan research literature. Telmisartan has been extensively investigated across multiple research streams: AT1 receptor pharmacology and RAS system research, PPAR-γ partial agonism research, cardiovascular research (particularly the ONTARGET and TRANSCEND trials for cardiovascular event research), metabolic research, and comparative ARB SAR studies. The oral capsule format uses microcrystalline cellulose (MCC) as the standard capsule excipient in a gelatin capsule shell. The compound is offered here strictly for laboratory research applications investigating AT1 receptor pharmacology, PPAR-γ partial agonism, and comparative research within the ARB research compound class.

Benefits (Research Focus)

• AT1 receptor antagonism research — studied as a selective angiotensin II receptor type 1 (AT1) antagonist research compound

• PPAR-γ partial agonism research — investigated as pharmacologically unique in the ARB class for additional PPAR-γ partial agonist activity — distinguishing telmisartan from other ARB research compounds

• Extended half-life ARB research — explored as the longest-half-life member of the ARB class (~24 hours plasma half-life) for extended-duration AT1 antagonism research

• Comparative ARB SAR research — examined alongside losartan, valsartan, olmesartan, candesartan, and irbesartan for comparative ARB structure-activity relationship studies

• Metabolic research applications — researched for PPAR-γ-mediated metabolic research endpoints in addition to AT1 receptor-mediated cardiovascular research

What Researchers Look At

• AT1 receptor binding affinity and antagonism kinetics in vascular research models

• PPAR-γ partial agonism selectivity and comparative activity versus full PPAR-γ agonists (thiazolidinediones)

• Comparative pharmacokinetic profiles versus other ARB research compounds (particularly plasma half-life comparisons)

• Cardiovascular research endpoints in preclinical research models

• Metabolic research endpoints including glucose and lipid metabolism markers

Quick Specs

• Form: Gelatin capsule

• Strength: 40 mg telmisartan per capsule

• Quantity: 30 capsules per bottle

• Total Telmisartan per Bottle: 1,200 mg (1.2 g)

• Other ingredients: Microcrystalline cellulose (MCC, excipient), gelatin capsule shell

• Appearance: Standard gelatin capsule presentation

• Purity: ≥99%

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Telmisartan

• Synonyms: BIBR 277 (Boehringer Ingelheim original development code); selective AT1 receptor antagonist research compound; angiotensin receptor blocker (ARB) research compound

• Class: Synthetic small molecule; selective angiotensin II receptor type 1 (AT1) antagonist; PPAR-γ partial agonist; benzimidazole chemistry class; oral ARB research compound

• Mechanism: Selective competitive antagonist at AT1 receptor + partial agonist activity at PPAR-γ receptor — unique dual mechanism within the ARB class

• Originator: Originally developed by Boehringer Ingelheim as BIBR 277

• Plasma half-life: ~24 hours (longest in the ARB class)

• Formula: C₃₃H₃₀N₄O₂

• Molecular Weight: ~514.62 g/mol

• CAS: 144701-48-4

⚠️ Disclaimer

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications in this presentation.

• Serious cardiovascular considerations: ARB research compounds have documented interactions with other cardiovascular medications, potassium-sparing diuretics, and lithium. Individuals with cardiovascular conditions, kidney disease, or on other medications should not use ARB compounds without medical supervision.

• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the capsule label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each batch, regardless of what the label or product image indicates.

Third-Party Testing

• [COA links for the Telmisartan 40mg × 30 capsule batch to be added once analytical testing is complete]